Literature DB >> 15607812

Cross-talk between dendritic cells and natural killer cells in viral infection.

Daniel M Andrews1, Christopher E Andoniou, Anthony A Scalzo, Serani L H van Dommelen, Morgan E Wallace, Mark J Smyth, Mariapia A Degli-Esposti.   

Abstract

Dendritic cells (DC), first characterized in 1973 by Steinman and Cohn, have been defined as the professional antigen presenting cells (APC), capable of activating naïve T cells much more efficiently than either B cells or macrophages. DC also capture and process antigen more efficiently than other APC, and offer MHC-antigen complexes to T cells at higher densities, and in the context of larger amounts of co-stimulatory molecules (i.e. CD40, CD80 and CD86) at the T cell-DC synapse. Although historically, the principal function of DC is the priming of naïve T cells, more recently they have also been shown to affect the functions of natural killer (NK) cells. Interactions between DC and NK cells may be critical in situations where immune surveillance requires efficient early activation of NK cells, as is the case during infections. This review aims to summarise the interactions that occur between DC and NK cells during viral infection.

Entities:  

Mesh:

Year:  2005        PMID: 15607812     DOI: 10.1016/j.molimm.2004.07.040

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  37 in total

Review 1.  Self or nonself? That is the question: sensing of cytomegalovirus infection by innate immune receptors.

Authors:  Michal Pyzik; Eve-Marie Gendron-Pontbriand; Nassima Fodil-Cornu; Silvia M Vidal
Journal:  Mamm Genome       Date:  2010-09-30       Impact factor: 2.957

Review 2.  Cell-mediated adaptive immune defense of the lungs.

Authors:  Jeffrey L Curtis
Journal:  Proc Am Thorac Soc       Date:  2005

3.  Combined therapy of transcatheter hepatic arterial embolization with intratumoral dendritic cell infusion for hepatocellular carcinoma: clinical safety.

Authors:  Y Nakamoto; E Mizukoshi; H Tsuji; Y Sakai; M Kitahara; K Arai; T Yamashita; K Yokoyama; N Mukaida; K Matsushima; O Matsui; S Kaneko
Journal:  Clin Exp Immunol       Date:  2007-02       Impact factor: 4.330

Review 4.  Natural killer cells in immunodefense against infective agents.

Authors:  Nicolas Zucchini; Karine Crozat; Thomas Baranek; Scott H Robbins; Marcus Altfeld; Marc Dalod
Journal:  Expert Rev Anti Infect Ther       Date:  2008-12       Impact factor: 5.091

Review 5.  Thunder and lightning: immunotherapy and oncolytic viruses collide.

Authors:  Alan Melcher; Kelley Parato; Cliona M Rooney; John C Bell
Journal:  Mol Ther       Date:  2011-04-19       Impact factor: 11.454

Review 6.  Natural killer cell activation by dendritic cells: balancing inhibitory and activating signals.

Authors:  Rosa Barreira da Silva; Christian Münz
Journal:  Cell Mol Life Sci       Date:  2011-08-23       Impact factor: 9.261

Review 7.  Concise review: immunologic lessons from solid organ transplantation for stem cell-based therapies.

Authors:  Andrea Loewendorf; Marie Csete
Journal:  Stem Cells Transl Med       Date:  2013-01-24       Impact factor: 6.940

8.  Analysis of the MCMV resistome by ENU mutagenesis.

Authors:  Karine Crozat; Philippe Georgel; Sophie Rutschmann; Navjiwan Mann; Xin Du; Kasper Hoebe; Bruce Beutler
Journal:  Mamm Genome       Date:  2006-05       Impact factor: 2.957

9.  Dendritic cells are required for optimal activation of natural killer functions following primary infection with herpes simplex virus type 1.

Authors:  Sadik H Kassim; Naveen K Rajasagi; Barry W Ritz; Stephen B Pruett; Elizabeth M Gardner; Robert Chervenak; Stephen R Jennings
Journal:  J Virol       Date:  2009-01-14       Impact factor: 5.103

10.  Primary human mDC1, mDC2, and pDC dendritic cells are differentially infected and activated by respiratory syncytial virus.

Authors:  Teresa R Johnson; Christina N Johnson; Kizzmekia S Corbett; Gretchen C Edwards; Barney S Graham
Journal:  PLoS One       Date:  2011-01-28       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.